Form 4: Kymera Therapeutics CEO Trades Shares

Nello Mainolfi, CEO of Kymera Therapeutics, executed a series of stock transactions on July 1, 2026, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Nello Mainolfi, Chief Executive Officer and Director of Kymera Therapeutics, Inc. (KYMR), reported transactions involving company common stock on July 1, 2026.
• These transactions were conducted under a Rule 10b5-1 trading plan established on March 24, 2026, which is designed to comply with affirmative defense conditions for insider trading.
• Mainolfi acquired 80,000 shares of common stock at a price of $2.08 per share.
• Concurrently, Mainolfi disposed of a total of 78,120 shares of common stock through multiple sales at weighted average prices ranging from $112.28 to $116.63.
• Following these transactions, Mainolfi beneficially owns 744,685 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the CEO acquired shares, the significant volume of sales under a pre-planned strategy balances out any immediate positive or negative sentiment.

Positives

• The acquisition of 80,000 shares at a lower price point ($2.08) could indicate a belief in future stock appreciation.
• The execution of transactions under a Rule 10b5-1 plan demonstrates adherence to compliance and pre-planned trading strategies, which can be viewed positively by investors seeking transparency.
• The CEO continues to hold a significant number of shares (744,685) directly, indicating continued substantial investment in the company.

Negatives

• The disposal of a substantial number of shares (78,120) at prices significantly higher than the acquisition price ($2.08) represents a considerable liquidation of holdings by the CEO.
• The weighted average sale prices indicate a range of market values at which the CEO divested shares, with the highest sale price being $116.63.

Risks

• While executed under a 10b5-1 plan, significant sales by a CEO can sometimes be interpreted by the market as a lack of confidence in near-term future performance, potentially impacting stock price.
• The difference between the acquisition price ($2.08) and the sale prices (up to $116.63) highlights the significant gains realized by the CEO, which may not be indicative of future returns for other investors.

Future Outlook

The filing itself does not contain forward-looking statements or guidance. However, the existence of a Rule 10b5-1 plan implies a pre-determined strategy for future transactions, the details of which are not disclosed in this filing.

Management Comments

• Transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026, adopted by the reporting person.
• The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in the footnotes.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures for insider transactions. The use of a Rule 10b5-1 plan by Kymera Therapeutics' CEO is a common practice for executives to manage their stock holdings in a compliant manner, especially in the biotechnology sector where stock price can be volatile.

Stakeholder Impact

• Shareholders: May interpret the CEO's sales as a signal, though the 10b5-1 plan mitigates concerns about opportunistic trading.
• Employees: The CEO's continued direct ownership may be seen as a positive sign of commitment.
• Management: The transactions are part of a pre-defined strategy, indicating adherence to corporate governance best practices.

Next Steps

• Continued monitoring of Nello Mainolfi's beneficial ownership and any future transactions reported on Form 4.
• Observation of market reaction to these reported transactions.

Key Dates

Keywords

Form 4, SEC Filing, Insider Trading, Rule 10b5-1, Stock Transaction, Nello Mainolfi, Kymera Therapeutics, KYMR, CEO, Beneficial Ownership, Stock Sale, Stock Purchase